Skip to main content
. 2016 Oct 22;5(1):1856. doi: 10.1186/s40064-016-3524-3

Table 2.

Clinical samples and cell lines, HPV test results, histology at time of sampling, and microRNA assay results

N:o Sample type HC2 Aptima LDR Luminex GeneXpert Histology H1 H2 H3 H5 H6 RNU6B UniSp6
1a Aptima + 16 Normal Neg Neg Neg Neg Neg 32 21
2a Aptima + 16 CIN3 Neg Neg Neg Neg Neg 33 21
3a Aptima + 16 CIN1 Neg Neg Neg Neg Neg 30 21
4a Aptima + 16 VAIN2 38 (1) Neg Neg Neg Neg 31 22
5a Aptima + 16 Normal Neg Neg Neg Neg Neg 31 22
6a Aptima + 16 CIN1 Neg Neg Neg Neg Neg 34 22
7a Aptima + 16 Normal Neg Neg Neg Neg Neg 32 21
8 Aptima + 16 Carcinoma Neg Neg Neg Neg Neg 32 22
9 Aptima − − Normal Neg Neg Neg Neg Neg 30 22
10 Aptima + 16 CIN1 Neg Neg Neg Neg Neg 32 22
11 Aptima − − Normal Neg Neg Neg Neg Neg 28 21
12 HC2 + N/A Neg Neg Neg Neg 51 (1) 24 21
13 HC2 + Metaplasia Neg Neg Neg Neg Neg 29 22
14 HC2 + N/A Neg Neg Neg Neg 49 (1) 26 22
15 HC2 + Normal Neg Neg Neg Neg Neg 31 22
16 ThinPrep + hrHPV CIN2 Neg Neg Neg Neg 57 (2, var) 30 22
17 ThinPrep + 16 CIN3 Neg Neg 44 50 (2, var) 48 (2, var) 24 22
18 ThinPrep + 18/45 Normal Neg Neg Neg 52 (1) Neg 28 22
19 ThinPrep + 18/45 AIS Neg 39 (1) 58 (1) Neg 51 (1) 28 21
20 ThinPrep + hrHPV CIN3 Neg Neg 49 (2, var) 54 (1) 44 (2, var) 25 22
21 ThinPrep + hrHPV Metaplasia 50 (1) Neg 50 (3, var) 56 (1) 42 (3, var) 24 22
22 ThinPrep + 16 CIN1 Neg Neg 45 (1) Neg 53 (1) 28 22
23 ThinPrep + 16, hrHPVb CIN1 Neg Neg 58 (2, var) Neg 52 (2, var) 27 22
24 ThinPrep + hrHPV CIN2 Neg 39 (1) Neg Neg Neg 33 23
25 ThinPrep + hrHPV CIN1 Neg Neg 50 (3, var) Neg 48 (3, var) 27 22
26 ThinPrep + hrHPV Condyloma Neg 39 (1) Neg 49 (1) 56 (1) 32 22
27 ThinPrep + 16 CIN2 Neg Neg 47 (3, var) Neg 45 (3, var) 24 22
28 ThinPrep + 18/45 Normal Neg Neg Neg Neg Neg 31 23
29 ThinPrep + hrHPV CIN1 Neg 37 (1) 55 (1) Neg 57 (1) 29 23
30 ThinPrep + 16 CIN3 50 (1) 39 (1) 45 (3, var) 48 (1) 45 (3, var) 25 22
31 ThinPrep + 16 CIN2 Neg Neg 50 (2, var) Neg 47 (2, var) 27 22
32 FFPE + 16, 18 16 SCC Negc Neg 45 (2, var) 54 (1) 48 (3, var) 31 22
33 FFPE − 6, 16 CIN3 52 (1)c Negc 47 (3, var) 48 (2, var) 39 (3, var) 33 22
34 FFPE + 16, 18 16 AIS 42 (1)c Negc 46 (3, var) 51 (2, var) 44 (3, var) 33 21
35 FFPE − 16, 18 16 CIN3 55 (1)c 57 (2, var)c 45 (3, var) 42 41 (3, var) 31 22
36 FFPE + 16 Adenocarcinoma Negc Negc 44 (3, var) 47 (2, var) 42 (3, var) 32 (2) 21
37 FFPE + 16, 18 16 SCC 57 (1)c Negc 46 (3, var) 47 (2, var) 41 33 21
38 FFPE − 16 16, 31, 35 CIN3 56 (1)c 40 (1) 47 (3, var) 47 (3, var) 40 (3, var) 33 22
39 FFPE N/A Adenocarcinoma Neg Neg 44 (3, var) 45 (1) 46 (3, var) 33 (2) 22
40 FFPE + 16, 18, 33 CIN3 Negc Neg 44 (3, var) 60 (1) 46 (3, var) 29 22
41 FFPE − 16 45 AIS 48 (1)c Neg 41 (3, var) 44 (2, var) 41 (3, var) 31 22
42 FFPE + 16, 58 16, 33, 58 CIN1 Negc 53 (1) 46 (3, var) 58 (1) 45 (3, var) 29 22
43 FFPE − 16, 58 16, 18, 58 AIS 50 (1)c Neg 56 (3, var) Neg 58 (1) 34 23
44 FFPE + 16, 18 33, 58 CIN1 Neg 44 (1) 45 (3, var) 52 (1) 45 (3, var) 33 22
45 FFPE + 16, 18 16 AIS Negc Negc 56 (2, var) Neg 53 (3, var) 38 (3, var) 24
46 FFPE − 16 16 CIN2, p16+ 55 (1)c Neg 57 (2) Neg 50 (3, var) 37 (2) 22
47 FFPE + 16, 52 16, 35, 52, 56 CIN2, p16+ Negc Neg 45 (3, var) Neg 47 (3, var) 32 22
48 FFPE − − − CIN2, p16+ 52 (1) Neg 59 (1) Neg 50 (3, var) 37 (2) 25
49 FFPE − 16, 18 16 Normal EE Neg Neg Neg Neg Neg 37 22
50 FFPE + 16 16 SCC Negc Negc 43 (1) 42 (1) 46 (3, var) 28 27
51b,c FFPE − 16 − Normal SE Neg Neg 44 (3, var) 53 (2, var) 40 (3, var) 31 22
52 HPK IA N/A 39 58 (1) 38 37 34 20 22
53 HPK II N/A 43 (3, var) Neg 38 (3, var) 39 (3, var) 34 26 21
54 CaSki N/A 42 (3, var) Neg 40 46 (3, var) 34 (3, var) 25 22
55 SiHa N/A 49 (3, var) Neg 39 (3, var) 48 (3, var) 39 (3, var) 28 21

HC2 hybrid capture 2, LDR ligase detection reaction (LDR-PCR microarray), H1–H6 HPV miRNAs, CIN1-3 cervical intraepithelial neoplasia grade 1–3, VAIN vaginal intraepithelial neoplasia, AIS adenocarcinoma in situ, SCC squamous cell carcinoma, EE endocervical epithelium, SE squamous epithelium. N/A not applicable or not available. Numbers in parentheses tell the number of replicates giving signal; var, multiple signals were not obtained within one cycle. Italicised values are interpreted as true positive findings

aAmplification of 40 cycles was performed; for all other samples 60 cycles of amplification was used

bPositive both for HPV 16 and another high-risk HPV type(s)

cExpression was seen in some replicates in previous work